Immune checkpoint blockade (ICB) therapy has greatly improved the survival of metastatic melanoma patients, with less severe side effects compared to more conventional forms of cancer treatment. While there are many molecules under investigation for new forms of ICB therapy, the most common targets of treatment are the ligands PD-L1 and CTLA4. By blocking their receptors, ICB treatment reactivates the anti-tumor T-cell response.
'Ultimately, it is all about understanding and treating patients better in the future.'
The National University of Singapore (NUS) Protein Biomarker Discovery Core Facility is one of the newest additions to the Olink core lab family. Established this year, the NUS Protein Biomarker Discovery Core Facility will offer full service of all Olink Target and Focus products, as well as Olink Explore. The core lab will focus on serving customers in Singapore and the Asia-Pacific region, where the demand for protein biomarker research has shot up in recent years. Lai Lai Yap, a senior laboratory manager in the NUS, describes their experience in becoming a certified core facility.
What makes for a successful Olink explore core lab partner? What type of training is involved, and how do the FAS team support and help core labs not just as they begin their core lab journey, but throughout their time as an Olink core lab partner? The following interview with Philippa Pettingill of the FAS team aims to answer such questions and more.
Olink’s core mission is ‘accelerating proteomics together’ with the scientific community. From the start, Olink has helped and supported countless researchers to carry out and advance their proteomics research using our PEA-based products and our team’s expertise.
To wrap up this month’s theme of Olink Explore 1536, here is an example of Olink Explore in action: To better understand the pathology of severe COVID-19 and why SARS-Co-V2 elicits a severe response in some patients, but not in others.
In our quest to realize the goal of precision medicine, it is crucial to develop accurate and precise proteomics platforms to measure biological variation in disease response in human populations. Antibody-based assay platforms allow the simultaneous measurement of multiple proteins, paving the way for proteomics analyses that result in meaningful insights into disease biology.